Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Autologous Thrombosomes in Healthy Subjects
NCT02223117Phase 1Completed
- Sponsor
- Cellphire Therapeutics, Inc.
- Start
- Sep 2014
- Primary completion
- Jul 2016
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial in Thrombocytopenia and hemorrhage comparing Thrombosomes with Placebo (2 arms). Primary endpoint: Number of Participants with Adverse Events as a Measure of Safety Evaluation at 60 days. Started Sep 2014; status: completed.
02
Drugs
Thrombosomes
03
Conditions
Thrombocytopeniahemorrhage
Beyond the preview
Go deeper on NCT02223117.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02223117.